Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases
Aim. To perform health-economic evaluation of trastuzumab emtansine (T-DM1) in patients with HER2+ breast cancer and CNS metastases. Materials and methods. Cost-effectiveness analysis along with sensitivity analysis and budget impact analysis were performed. Direct medical costs and indirect costs (...
Main Authors: | A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, D. R. Naskhletashvili |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2018-05-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/82 |
Similar Items
-
An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2019-04-01) -
Сравнительный фармакоэкономический анализ применения анастрозола, летрозола и экземестана при адъювантной терапии рака молочной железы
Published: (2018-06-01) -
Кабазитаксел во второй линии химиотерапии рака предстательной железы — клинико-экономическая оценка
Published: (2018-06-01) -
Pharmacoeconomic analysis of adjuvant use of zonisamide therapy resistant partial epilepsy in adults
by: D. Yu. Belousov, et al.
Published: (2018-06-01) -
Health technology assessment of colorectal cancer chemotherapy with afl ibercept
by: A. S. Kolbin, et al.
Published: (2018-05-01)